Pharmaceutical Market Europe • October 2022 • 3

COMMENT

Changing the future of oncology

In this issue, our cover article focuses on the exciting breakthroughs that are happening in the area of oncology, many of which were announced at the European Society for Medical Oncology (ESMO) Congress.

This year, ESMO held its 2022 congress in Paris as a hybrid event. As Michael Smith and Marin Martinis wrote in their article, it was an exciting place to be: “Standing ovations at medical congresses aren’t an everyday event, but they’re becoming a trend in cancer research. Just like ASCO’s Chicago equivalent a few months earlier, the scientific innovation on display was enough to make delegates rise up from their seats.

“ESMO confirmed that these are exciting times in cancer research. And, in the post-COVID era of hybrid events, it reaffirmed the value of traditional medical congresses, highlighting a renewed opportunity for creative comms to play an even bigger role in transforming oncology care.” Read more about this fascinating event on page 16.

In their article on cell and gene therapies, Brian Huber and Tamie Joeckel talk about managing the complexities of current generation CAR-T therapies: “While the potential of CAR-T therapies is extraordinary, the complexity and cost of their supply chains jeopardise scalability and long-term commercialisation. One of the primary reasons for this complexity is their personalisation. While ‘traditional’ therapeutics are produced in large batches for many people at once, CAR-Ts are typically manufactured in smaller – sometimes single dose – batches.” Read more about the advances in CAR-T therapy on page 18.

Looking ahead, our November issue will look at clinical trial diversity and the critical benefits of increased representation. Some diseases disproportionately impact certain racial and ethnic groups, and these diseases often occur in populations that have historically been underrepresented and understudied. Ensuring increased representation in clinical trials is therefore vital in tackling healthcare disparities and enabling health equity.

If you would like to make your voice heard on this topic, please get in touch at sales@pmlive.com

I hope you enjoy this issue!

Image

Iona Everson
Group Managing Editor

Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at  www.pmlive.com/register

Image

THE TEAM
Editorial:
Group Managing Editor
Iona Everson

Journalist/editorial assistant
Fleur Jeffries
Emily Kimber


Studio:
Executive Director
Karl Equi

Sales:
Business Director
Tara Lovegrove

EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals

PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201

CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com

Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2022 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW

Image